Nymox Pharmaceutical annual revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Revenue Growth & History (NYMXF)
Nymox Pharmaceutical reported $0 in revenue for fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | $0 | — |
| 2021 | 2021-12-31 | $0 | −$5,000 | −100.00% |
| 2020 | 2020-12-31 | $5,000 | −$111,000 | −95.69% |
| 2019 | 2019-12-31 | $116,000 | −$183,000 | −61.20% |
| 2018 | 2018-12-31 | $299,000 | $75,000 | +33.48% |
| 2017 | 2017-12-31 | $224,000 | −$60,000 | −21.13% |
| 2016 | 2016-12-31 | $284,000 | −$2.5M | −89.71% |
| 2015 | 2015-12-31 | $2.8M | — | — |
Nymox Pharmaceutical quarterly revenue
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q4.24
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $0 | $0 | — |
| Q3 2023 | 2023-09-30 | $0 | $0 | — |
| Q2 2023 | 2023-06-30 | $0 | $0 | — |
| Q1 2023 | 2023-03-31 | $0 | $0 | — |
| Q4 2022 | 2022-12-31 | $0 | $0 | — |
| Q3 2022 | 2022-09-30 | $0 | $0 | — |
| Q2 2022 | 2022-06-30 | $0 | $0 | — |
| Q1 2022 | 2022-03-31 | $0 | $0 | — |
| Q4 2021 | 2021-12-31 | $0 | $0 | — |
| Q3 2021 | 2021-09-30 | $0 | $0 | — |
| Q2 2021 | 2021-06-30 | $0 | $0 | — |
| Q1 2021 | 2021-03-31 | $0 | −$5,000 | −100.00% |
| Q4 2020 | 2020-12-31 | $0 | −$27,000 | −100.00% |
| Q3 2020 | 2020-09-30 | $0 | −$39,000 | −100.00% |
| Q2 2020 | 2020-06-30 | $0 | −$20,000 | −100.00% |
| Q1 2020 | 2020-03-31 | $5,000 | −$25,000 | −83.33% |
| Q4 2019 | 2019-12-31 | $27,000 | $8,000 | +42.11% |
| Q3 2019 | 2019-09-30 | $39,000 | −$1,000 | −2.50% |
| Q2 2019 | 2019-06-30 | $20,000 | −$68,000 | −77.27% |
| Q1 2019 | 2019-03-31 | $30,000 | −$122,000 | −80.26% |
| Q4 2018 | 2018-12-31 | $19,000 | −$87,000 | −82.08% |
| Q3 2018 | 2018-09-30 | $40,000 | $9,000 | +29.03% |
| Q2 2018 | 2018-06-30 | $88,000 | $79,000 | +877.78% |
| Q1 2018 | 2018-03-31 | $152,000 | $74,000 | +94.87% |
| Q4 2017 | 2017-12-31 | $106,000 | — | — |
| Q3 2017 | 2017-09-30 | $31,000 | — | — |
| Q2 2017 | 2017-06-30 | $9,000 | — | — |
| Q1 2017 | 2017-03-31 | $78,000 | — | — |
Nymox Pharmaceutical revenue growth trends
Nymox Pharmaceutical's latest reported quarter, Q4 2024, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Nymox Pharmaceutical source filings ↗